Hillstream BioPharma, Inc.
HILS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,392 | $3,560 | $2,278 | $1,843 |
| G&A Expenses | $6,042 | $5,896 | $4,604 | $1,365 |
| SG&A Expenses | $6,042 | $5,896 | $4,604 | $1,365 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,434 | $9,455 | $6,882 | $3,208 |
| Operating Income | -$12,434 | -$9,455 | -$6,882 | -$3,208 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $236 | $136 | -$1,591 | $1,001 |
| Pre-Tax Income | -$12,198 | -$9,319 | -$8,473 | -$2,207 |
| Tax Expense | $0 | $0 | $0 | $831 |
| Net Income | -$12,198 | -$9,319 | -$8,473 | -$3,038 |
| % Margin | – | – | – | – |
| EPS | -9.41 | -7.14 | -0.75 | -0.3 |
| % Growth | -31.8% | -852% | -150% | – |
| EPS Diluted | -9.41 | -7.14 | -0.75 | -0.3 |
| Weighted Avg Shares Out | 1,296 | 1,305 | 11,233 | 10,295 |
| Weighted Avg Shares Out Dil | 1,296 | 1,305 | 11,233 | 10,295 |
| Supplemental Information | – | – | – | – |
| Interest Income | $250 | $153 | $0 | $0 |
| Interest Expense | -$14 | -$17 | $1,591 | $831 |
| Depreciation & Amortization | $0 | $168 | $1,569,003 | $1,833 |
| EBITDA | -$12,434 | -$9,455 | -$6,882 | $457 |
| % Margin | – | – | – | – |